Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children.
Realm’s lead drug candidate, PR022, which utilizes the Company’s proprietary immunomodulatory technology, is in a Phase 2 clinical trial for the treatment of Atopic Dermatitis. The Company is also exploring potential efficacy of its technology in other dermatology indications, including Acne Vulgaris and Psoriasis, as well as other therapeutic areas.
